A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer

David Y. Takeda, S. Spisák, Ji Heui Seo, Connor Bell, Edward O'Connor, Keegan Korthauer, Dezső Ribli, I. Csabai, N. Solymosi, Zoltán Szállási, David R. Stillman, Paloma Cejas, Xintao Qiu, Henry W. Long, Viktória Tisza, Pier Vitale Nuzzo, Mersedeh Rohanizadegan, Mark M. Pomerantz, William C. Hahn, Matthew L. Freedman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Increased androgen receptor (AR) activity drives therapeutic resistance in advanced prostate cancer. The most common resistance mechanism is amplification of this locus presumably targeting the AR gene. Here, we identify and characterize a somatically acquired AR enhancer located 650 kb centromeric to the AR. Systematic perturbation of this enhancer using genome editing decreased proliferation by suppressing AR levels. Insertion of an additional copy of this region sufficed to increase proliferation under low androgen conditions and to decrease sensitivity to enzalutamide. Epigenetic data generated in localized prostate tumors and benign specimens support the notion that this region is a developmental enhancer. Collectively, these observations underscore the importance of epigenomic profiling in primary specimens and the value of deploying genome editing to functionally characterize noncoding elements. More broadly, this work identifies a therapeutic vulnerability for targeting the AR and emphasizes the importance of regulatory elements as highly recurrent oncogenic drivers. Activation and amplification of an enhancer upstream of the androgen receptor locus drives progression of metastatic castration-resistant prostate cancer.

Original languageEnglish
JournalCell
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Genes
Epigenomics
Amplification
Castration
Androgens
Tumors
Prostate
Chemical activation
Therapeutics
Neoplasms

Keywords

  • androgen receptor
  • castrate resistant
  • enhancer
  • epigenetic
  • epigenome editing
  • epigenomic
  • functional genomics
  • genome editing
  • prostate cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Takeda, D. Y., Spisák, S., Seo, J. H., Bell, C., O'Connor, E., Korthauer, K., ... Freedman, M. L. (Accepted/In press). A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. https://doi.org/10.1016/j.cell.2018.05.037

A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. / Takeda, David Y.; Spisák, S.; Seo, Ji Heui; Bell, Connor; O'Connor, Edward; Korthauer, Keegan; Ribli, Dezső; Csabai, I.; Solymosi, N.; Szállási, Zoltán; Stillman, David R.; Cejas, Paloma; Qiu, Xintao; Long, Henry W.; Tisza, Viktória; Nuzzo, Pier Vitale; Rohanizadegan, Mersedeh; Pomerantz, Mark M.; Hahn, William C.; Freedman, Matthew L.

In: Cell, 01.01.2018.

Research output: Contribution to journalArticle

Takeda, DY, Spisák, S, Seo, JH, Bell, C, O'Connor, E, Korthauer, K, Ribli, D, Csabai, I, Solymosi, N, Szállási, Z, Stillman, DR, Cejas, P, Qiu, X, Long, HW, Tisza, V, Nuzzo, PV, Rohanizadegan, M, Pomerantz, MM, Hahn, WC & Freedman, ML 2018, 'A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer', Cell. https://doi.org/10.1016/j.cell.2018.05.037
Takeda, David Y. ; Spisák, S. ; Seo, Ji Heui ; Bell, Connor ; O'Connor, Edward ; Korthauer, Keegan ; Ribli, Dezső ; Csabai, I. ; Solymosi, N. ; Szállási, Zoltán ; Stillman, David R. ; Cejas, Paloma ; Qiu, Xintao ; Long, Henry W. ; Tisza, Viktória ; Nuzzo, Pier Vitale ; Rohanizadegan, Mersedeh ; Pomerantz, Mark M. ; Hahn, William C. ; Freedman, Matthew L. / A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. In: Cell. 2018.
@article{c00ed6bb3a6f4b2e8cb775afbaf7f28b,
title = "A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer",
abstract = "Increased androgen receptor (AR) activity drives therapeutic resistance in advanced prostate cancer. The most common resistance mechanism is amplification of this locus presumably targeting the AR gene. Here, we identify and characterize a somatically acquired AR enhancer located 650 kb centromeric to the AR. Systematic perturbation of this enhancer using genome editing decreased proliferation by suppressing AR levels. Insertion of an additional copy of this region sufficed to increase proliferation under low androgen conditions and to decrease sensitivity to enzalutamide. Epigenetic data generated in localized prostate tumors and benign specimens support the notion that this region is a developmental enhancer. Collectively, these observations underscore the importance of epigenomic profiling in primary specimens and the value of deploying genome editing to functionally characterize noncoding elements. More broadly, this work identifies a therapeutic vulnerability for targeting the AR and emphasizes the importance of regulatory elements as highly recurrent oncogenic drivers. Activation and amplification of an enhancer upstream of the androgen receptor locus drives progression of metastatic castration-resistant prostate cancer.",
keywords = "androgen receptor, castrate resistant, enhancer, epigenetic, epigenome editing, epigenomic, functional genomics, genome editing, prostate cancer",
author = "Takeda, {David Y.} and S. Spis{\'a}k and Seo, {Ji Heui} and Connor Bell and Edward O'Connor and Keegan Korthauer and Dezső Ribli and I. Csabai and N. Solymosi and Zolt{\'a}n Sz{\'a}ll{\'a}si and Stillman, {David R.} and Paloma Cejas and Xintao Qiu and Long, {Henry W.} and Vikt{\'o}ria Tisza and Nuzzo, {Pier Vitale} and Mersedeh Rohanizadegan and Pomerantz, {Mark M.} and Hahn, {William C.} and Freedman, {Matthew L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cell.2018.05.037",
language = "English",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",

}

TY - JOUR

T1 - A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer

AU - Takeda, David Y.

AU - Spisák, S.

AU - Seo, Ji Heui

AU - Bell, Connor

AU - O'Connor, Edward

AU - Korthauer, Keegan

AU - Ribli, Dezső

AU - Csabai, I.

AU - Solymosi, N.

AU - Szállási, Zoltán

AU - Stillman, David R.

AU - Cejas, Paloma

AU - Qiu, Xintao

AU - Long, Henry W.

AU - Tisza, Viktória

AU - Nuzzo, Pier Vitale

AU - Rohanizadegan, Mersedeh

AU - Pomerantz, Mark M.

AU - Hahn, William C.

AU - Freedman, Matthew L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Increased androgen receptor (AR) activity drives therapeutic resistance in advanced prostate cancer. The most common resistance mechanism is amplification of this locus presumably targeting the AR gene. Here, we identify and characterize a somatically acquired AR enhancer located 650 kb centromeric to the AR. Systematic perturbation of this enhancer using genome editing decreased proliferation by suppressing AR levels. Insertion of an additional copy of this region sufficed to increase proliferation under low androgen conditions and to decrease sensitivity to enzalutamide. Epigenetic data generated in localized prostate tumors and benign specimens support the notion that this region is a developmental enhancer. Collectively, these observations underscore the importance of epigenomic profiling in primary specimens and the value of deploying genome editing to functionally characterize noncoding elements. More broadly, this work identifies a therapeutic vulnerability for targeting the AR and emphasizes the importance of regulatory elements as highly recurrent oncogenic drivers. Activation and amplification of an enhancer upstream of the androgen receptor locus drives progression of metastatic castration-resistant prostate cancer.

AB - Increased androgen receptor (AR) activity drives therapeutic resistance in advanced prostate cancer. The most common resistance mechanism is amplification of this locus presumably targeting the AR gene. Here, we identify and characterize a somatically acquired AR enhancer located 650 kb centromeric to the AR. Systematic perturbation of this enhancer using genome editing decreased proliferation by suppressing AR levels. Insertion of an additional copy of this region sufficed to increase proliferation under low androgen conditions and to decrease sensitivity to enzalutamide. Epigenetic data generated in localized prostate tumors and benign specimens support the notion that this region is a developmental enhancer. Collectively, these observations underscore the importance of epigenomic profiling in primary specimens and the value of deploying genome editing to functionally characterize noncoding elements. More broadly, this work identifies a therapeutic vulnerability for targeting the AR and emphasizes the importance of regulatory elements as highly recurrent oncogenic drivers. Activation and amplification of an enhancer upstream of the androgen receptor locus drives progression of metastatic castration-resistant prostate cancer.

KW - androgen receptor

KW - castrate resistant

KW - enhancer

KW - epigenetic

KW - epigenome editing

KW - epigenomic

KW - functional genomics

KW - genome editing

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85048223491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048223491&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2018.05.037

DO - 10.1016/j.cell.2018.05.037

M3 - Article

C2 - 29909987

AN - SCOPUS:85048223491

JO - Cell

JF - Cell

SN - 0092-8674

ER -